SG11201807590SA - Transfected t-cells and t-cell receptors for use in immunotherapy against cancers - Google Patents
Transfected t-cells and t-cell receptors for use in immunotherapy against cancersInfo
- Publication number
- SG11201807590SA SG11201807590SA SG11201807590SA SG11201807590SA SG11201807590SA SG 11201807590S A SG11201807590S A SG 11201807590SA SG 11201807590S A SG11201807590S A SG 11201807590SA SG 11201807590S A SG11201807590S A SG 11201807590SA SG 11201807590S A SG11201807590S A SG 11201807590SA
- Authority
- SG
- Singapore
- Prior art keywords
- cells
- international
- present description
- cell receptors
- peptides
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 8
- 108091008874 T cell receptors Proteins 0.000 title abstract 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 6
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 5
- 238000009169 immunotherapy Methods 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/158116 Al 21 September 2017 (21.09.2017) WIPO I PCT 111111111111110111011111111111010111110 011111111H 011101111111111111111110111111 (51) International Patent Classification: C07K 14/725 (2006.01) C07K 14/74 (2006.01) A61K 39/00 (2006.01) C12N 5/0783 (2010.01) (21) International Application Number: PCT/EP2017/056289 (22) International Filing Date: 16 March 2017 (16.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1604494.3 16 March 2016 (16.03.2016) GB 62/308,970 16 March 2016 (16.03.2016) US (71) Applicant: IMMATICS BIOTECHNOLOGIES GMBH [DE/DE]; Paul-Ehrlich-StraBe 15, 72076 Tilbingen (DE). (72) Inventors: MAURER, Dominik; Fleinerweg 7, 72116 Moessingen (DE). ALTEN, Leonie; WeiBdomweg 14, App. 161, 72076 Tilbingen (DE). BUNK, Sebastian; Staeudach 182, 72074 Tilbingen (DE). (74) Agent: BOEHMERT & BOEHMERT; Jan B. KRAUSS, Pettenkoferstrasse 22, 80336 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) W O 20 17 / 15 8 116 Al (54) Title: TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS (57) : The present description relates to T-cell receptors (TCRs) binding to tumor- associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. In particular, the present description relates to TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as IGF2BP3-001 have the amino acid sequence of KIQEILTQV (SEQ ID NO:1). The present description further relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tu- mor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate an - ti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histo - compatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding mo - lecules.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662308970P | 2016-03-16 | 2016-03-16 | |
| GBGB1604494.3A GB201604494D0 (en) | 2016-03-16 | 2016-03-16 | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
| PCT/EP2017/056289 WO2017158116A1 (en) | 2016-03-16 | 2017-03-16 | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807590SA true SG11201807590SA (en) | 2018-10-30 |
Family
ID=55952419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807590SA SG11201807590SA (en) | 2016-03-16 | 2017-03-16 | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10537624B2 (en) |
| EP (1) | EP3430037B1 (en) |
| JP (1) | JP6929867B2 (en) |
| KR (1) | KR102266721B1 (en) |
| CN (1) | CN108884143A (en) |
| AU (1) | AU2017235069B2 (en) |
| BR (1) | BR112018067989A2 (en) |
| CA (1) | CA3017419A1 (en) |
| CR (1) | CR20180490A (en) |
| EA (1) | EA201891759A1 (en) |
| GB (1) | GB201604494D0 (en) |
| MA (2) | MA43328B2 (en) |
| MX (1) | MX2018011223A (en) |
| PE (1) | PE20190124A1 (en) |
| SG (1) | SG11201807590SA (en) |
| TW (1) | TWI788284B (en) |
| UA (1) | UA124532C2 (en) |
| WO (1) | WO2017158116A1 (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3430037T (en) * | 2016-03-16 | 2022-11-23 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
| EP3578650A4 (en) * | 2017-02-06 | 2021-03-24 | National Cancer Center Japan | Novel t-cell receptor |
| WO2019070541A1 (en) | 2017-10-03 | 2019-04-11 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
| SG11202007622SA (en) | 2018-02-11 | 2020-09-29 | Memorial Sloan Kettering Cancer Center | Non-hla restricted t cell receptors and uses thereof |
| WO2019157524A1 (en) * | 2018-02-12 | 2019-08-15 | Fred Hutchinson Cancer Research Center | Cyclin a1 specific t cell receptors and uses thereof |
| CN112119087A (en) * | 2018-03-14 | 2020-12-22 | 基因医疗免疫疗法有限责任公司 | Inducible T cell receptor and uses thereof |
| MX2020010460A (en) * | 2018-04-05 | 2021-01-29 | Juno Therapeutics Inc | T cell receptors and engineered cells expressing same. |
| EP3854802A4 (en) * | 2018-09-21 | 2022-10-12 | XLifeSc, Ltd. | High affinity t cell receptor for recognizing afp antigen |
| WO2020123388A1 (en) * | 2018-12-11 | 2020-06-18 | Board Of Regents, The University Of Texas System | Radiotherapies and uses thereof |
| KR20210106494A (en) | 2018-12-20 | 2021-08-30 | 아바 라이프사이언스 게엠베하 | How to Select a Biological Binding Molecule |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| DE102019108125B4 (en) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | CD28 T-CELL CULTURES, COMPOSITIONS AND METHODS OF USE |
| JP2022534716A (en) | 2019-05-27 | 2022-08-03 | イマティクス ユーエス，アイエヌシー． | Viral vectors and their use in adoptive cell therapy |
| CN110357953B (en) * | 2019-07-17 | 2022-05-03 | 深圳市因诺转化医学研究院 | TCR recognizing human cytomegalovirus pp65 antigen |
| EP4003375A4 (en) * | 2019-07-31 | 2023-09-06 | Forty Seven, Inc. | Depletion regimes for engineered t-cell or nk-cell therapy |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| WO2021050948A1 (en) * | 2019-09-12 | 2021-03-18 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP2023515131A (en) | 2020-02-24 | 2023-04-12 | イマティクス ユーエス，アイエヌシー． | Methods of expanding T cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (en) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND RELATED PROCEDURES |
| TW202227616A (en) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | Methods for isolating cd8+ selected t cells |
| EP4271481A2 (en) | 2020-12-31 | 2023-11-08 | Immatics US, Inc. | Cd8 polypeptides, compositions, and methods of using thereof |
| DE102021100038A1 (en) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | MODIFIED CD8 POLYPEPTIDES, COMPOSITIONS AND METHODS OF USE THEREOF |
| CA3217739A1 (en) | 2021-05-05 | 2022-11-10 | Sebastian Bunk | Bma031 antigen binding polypeptides |
| WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| US20230142468A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
| WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101130597B1 (en) | 2005-09-13 | 2012-04-02 | 다카라 바이오 가부시키가이샤 | T-cell receptor and nucleic acid encoding the receptor |
| AU2014271235B2 (en) * | 2008-10-01 | 2017-03-02 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including neuronal and brain tumors |
| PT2172211E (en) | 2008-10-01 | 2015-03-09 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers |
| TW201124530A (en) | 2009-12-01 | 2011-07-16 | Oncotherapy Science Inc | IMP-3 oligopeptides and vaccines including the same |
| HUE048014T2 (en) * | 2012-09-14 | 2020-05-28 | Us Health | T cell receptors recognizing mhc class ii-restricted mage-a3 |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
-
2016
- 2016-03-16 GB GBGB1604494.3A patent/GB201604494D0/en not_active Ceased
-
2017
- 2017-03-16 SG SG11201807590SA patent/SG11201807590SA/en unknown
- 2017-03-16 US US15/461,020 patent/US10537624B2/en active Active
- 2017-03-16 CA CA3017419A patent/CA3017419A1/en not_active Abandoned
- 2017-03-16 TW TW106108697A patent/TWI788284B/en active
- 2017-03-16 WO PCT/EP2017/056289 patent/WO2017158116A1/en active Application Filing
- 2017-03-16 MA MA43328A patent/MA43328B2/en unknown
- 2017-03-16 EA EA201891759A patent/EA201891759A1/en unknown
- 2017-03-16 KR KR1020187029658A patent/KR102266721B1/en active IP Right Grant
- 2017-03-16 BR BR112018067989A patent/BR112018067989A2/en not_active IP Right Cessation
- 2017-03-16 MA MA45309A patent/MA45309B1/en unknown
- 2017-03-16 EP EP17710963.4A patent/EP3430037B1/en active Active
- 2017-03-16 PE PE2018001777A patent/PE20190124A1/en unknown
- 2017-03-16 CN CN201780017419.XA patent/CN108884143A/en active Pending
- 2017-03-16 CR CR20180490A patent/CR20180490A/en unknown
- 2017-03-16 UA UAA201809121A patent/UA124532C2/en unknown
- 2017-03-16 JP JP2018548050A patent/JP6929867B2/en active Active
- 2017-03-16 AU AU2017235069A patent/AU2017235069B2/en not_active Ceased
- 2017-03-16 MX MX2018011223A patent/MX2018011223A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI788284B (en) | 2023-01-01 |
| AU2017235069B2 (en) | 2020-05-07 |
| BR112018067989A2 (en) | 2019-02-05 |
| MA43328B2 (en) | 2022-02-28 |
| TW201742873A (en) | 2017-12-16 |
| UA124532C2 (en) | 2021-10-05 |
| MA45309A (en) | 2019-01-23 |
| US10537624B2 (en) | 2020-01-21 |
| JP2019512242A (en) | 2019-05-16 |
| KR102266721B1 (en) | 2021-06-17 |
| GB201604494D0 (en) | 2016-04-27 |
| AU2017235069A1 (en) | 2018-10-04 |
| MX2018011223A (en) | 2018-11-22 |
| EP3430037A1 (en) | 2019-01-23 |
| WO2017158116A1 (en) | 2017-09-21 |
| MA43328A1 (en) | 2019-05-31 |
| EP3430037B1 (en) | 2022-08-31 |
| MA45309B1 (en) | 2023-01-31 |
| CN108884143A (en) | 2018-11-23 |
| CA3017419A1 (en) | 2017-09-21 |
| US20170312350A1 (en) | 2017-11-02 |
| KR20180122430A (en) | 2018-11-12 |
| EA201891759A1 (en) | 2019-02-28 |
| CR20180490A (en) | 2019-01-10 |
| PE20190124A1 (en) | 2019-01-17 |
| JP6929867B2 (en) | 2021-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807590SA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| SG11201807868VA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
| SG11201807300PA (en) | Uterine cancer treatments | |
| SG11201806951TA (en) | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers | |
| SG11201806577UA (en) | Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers | |
| SG11201906198PA (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
| SG11201908023YA (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
| SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
| SG11201801670YA (en) | Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers | |
| SG11201801384YA (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
| SG11201801756WA (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
| SG11201909153UA (en) | Peptides and combination thereof for use in the immunotherapy against cancers | |
| SG11201908527SA (en) | High affinity mage-a1-specific tcrs and uses thereof | |
| SG11201808783XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
| SG11201809781PA (en) | Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers | |
| SG11201907402SA (en) | Population-based immunogenic peptide identification platform | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201908540PA (en) | Stable antibody formulation | |
| SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
| SG11201806150RA (en) | Psma and cd3 bispecific t cell engaging antibody constructs | |
| SG11201909058WA (en) | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers | |
| SG11201808629UA (en) | Immunotherapy against melanoma and other cancers | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof |